^
    Back
    Association details:
    Biomarker:KLF4 overexpression
    Cancer:Nasopharyngeal Carcinoma
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Biomed Central
    Title:

    Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma

    Excerpt:
    Moreover, in the 168 cases treated with cetuximab in addition to basic treatment...56 showed a high expression of KLF4 in the nucleus that can cause poor prognosis of nasopharyngeal carcinoma (P = 0.011).
    DOI:
    10.1186/s12967-018-1561-0